147 related articles for article (PubMed ID: 32908255)
1. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
Hao S; Lin P; Medeiros LJ; Fang L; Carballo-Zarate AA; Konoplev SN; Sargent RL; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Lu X
Mod Pathol; 2017 Oct; 30(10):1378-1386. PubMed ID: 28664940
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
4. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.
Carballo-Zarate AA; Medeiros LJ; Fang L; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Hao S; Shen Q; Orlowski RZ; Lin P; Lu X
Mod Pathol; 2017 Jun; 30(6):843-853. PubMed ID: 28281554
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications.
Bahmanyar M; Qi X; Chang H
Leuk Res; 2013 Dec; 37(12):1726-8. PubMed ID: 24169086
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
[TBL] [Abstract][Full Text] [Related]
8. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
[TBL] [Abstract][Full Text] [Related]
9. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
Shaughnessy J
Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
Chang H; Qi X; Trieu Y; Xu W; Reader JC; Ning Y; Reece D
Br J Haematol; 2006 Nov; 135(4):486-91. PubMed ID: 16995883
[TBL] [Abstract][Full Text] [Related]
11. Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore.
Lim AS; Krishnan S; Lim TH; See K; Ng YJ; Tan YM; Choo N; Lau LC; Tien SL; Ma J; Tan D
Indian J Hematol Blood Transfus; 2014 Dec; 30(4):253-8. PubMed ID: 25435723
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
Wang Y; Li Q; Xing S; Zhang H; Li D
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
[TBL] [Abstract][Full Text] [Related]
15. [Influence of Chromosome Abnormality on Therapeutic Efficacy and Prognosis of Newly Diagnosed Multiple Myeloma Treated with Bortezomib].
Sun C; Wang J; Guo HF; Zhou X; Shen YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):142-146. PubMed ID: 28245391
[TBL] [Abstract][Full Text] [Related]
16. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib].
Wang DM; Chen YY; Meng Z; Zhang YX; Guo SQ; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1221-1227. PubMed ID: 32798402
[TBL] [Abstract][Full Text] [Related]
18. [Detection of the Cytogenetic Aberrations in Multiple Myeloma by Using Microrray Comparative Genomic Hybridization].
Wang YF; Wang H; Xi LY; Zhang ZH; Wang J; Dong F; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1389-1395. PubMed ID: 30295256
[TBL] [Abstract][Full Text] [Related]
19. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
Zhan F; Colla S; Wu X; Chen B; Stewart JP; Kuehl WM; Barlogie B; Shaughnessy JD
Blood; 2007 Jun; 109(11):4995-5001. PubMed ID: 17303695
[TBL] [Abstract][Full Text] [Related]
20. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
